CLL-1029: A Network Meta-Analysis of Efficacy of Zanubrutinib vs Fixed-Duration Acalabrutinib Plus Venetoclax in Treatment-Naïve Chronic Lymphocytic Leukemia
Mazyar Shadman(University of Washington), Talha Munir(Leeds Teaching Hospitals NHS Trust), Rhys Williams(Cambridge Collaborative (United States)), Keri Yang(Universidad San Carlos), Sheng Xu(Danone (China))
Cited by 0
Related Papers
Ibrutinib‐associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non‐Hodgkin lymphoma: An observational study
|Mycoses|2019|80
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
|The Lancet Haematology|2024|37
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2025|26